Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer
Completed · Phase 3 · Has a placebo group
Conditions studied: Bladder Cancer
In brief
RATIONALE: Drugs used in chemotherapy, such as fenretinide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether fenretinide is more effective than a placebo in preventing the recurrence of bladder cancer after surgery to remove the tumor. PURPOSE: This randomized phase III trial is studying fenretinide to see how well it works compared to a placebo in treating patients who are at risk for recurrent bladder cancer following surgery to remove the tumor.
Key facts
- Study ID
- NCT00004154
- Run by
- M.D. Anderson Cancer Center
- People needed
- 111
- Starts
- 1998-07-30
- Expected to finish
- 2005-03-01
- Last updated by the study team
- 2018-11-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Texas - MD Anderson Cancer Center — Houston, Texas, United States
- Baylor College of Medicine — Houston, Texas, United States
- Veterans Affairs Medical Center - Seattle — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.